Zsolt G. Nagy

Szentkirályi Street 47
Budapest, BU 1088, Hungary

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Two B or not two B; the question of bendamustine dosing in low grade lymphoma.

Two B or not two B; the question of bendamustine dosing in low grade lymphoma.

Journal: Pathology oncology research : POR

Published: June 11, 2025

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Journal: Blood advances

Published: February 24, 2025

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy.

Resistance mechanisms and clonal dynamics in mantle cell lymphoma treated with sequential BTKi and venetoclax therapy.

Journal: The Journal of pathology

Published: January 07, 2025

Digital PCR-based quantification of miR-181a in the cerebrospinal fluid aids patient stratification in pediatric acute lymphoblastic leukemia.

Digital PCR-based quantification of miR-181a in the cerebrospinal fluid aids patient stratification in pediatric acute lymphoblastic leukemia.

Journal: Scientific reports

Published: August 29, 2024

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.

Bortezomib, melphalan, and prednisone with or without daratumumab in transplant-ineligible patients with newly diagnosed multiple myeloma (ALCYONE): final analysis of an open-label, randomised, multicentre, phase 3 trial.

Journal: The Lancet. Oncology

Published: May 06, 2024

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options.

Journal: Annals of hematology

Published: January 12, 2024

In-vitro accuracy of a novel jaw-tracking technology.

In-vitro accuracy of a novel jaw-tracking technology.

Journal: Journal of dentistry

Published: August 13, 2023

Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.

Low-burden TP53 mutations represent frequent genetic events in CLL with an increased risk for treatment initiation.

Journal: The journal of pathology. Clinical research

Published: July 26, 2023

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.

Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study.

Journal: Haematologica

Published: May 12, 2023

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.

Landscape of BCL2 Resistance Mutations in a Real-World Cohort of Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia Treated with Venetoclax.

Journal: International journal of molecular sciences

Published: February 02, 2023

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.

Targeted Venetoclax Therapy in t(11;14) Multiple Myeloma: Real World Data From Seven Hungarian Centers.

Journal: Pathology oncology research : POR

Published: December 19, 2021

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma.

Journal: Haematologica

Published: August 19, 2021

Showing 1-12 of 40

Last Updated: 09/26/2026